We are pleased to announce the official launch of our brand-new TRICALS website! Our new website provides up-to-date information about TRICALS and has many new features.
What’s new?
We have reviewed all the existing information and added a range of new content to the website, such as:
- you will easily find new information about upcoming clinical trials, such as the MAGNET platform trial.
- We will now keep you updated about developments and achievements of TRICALS on our News page. So keep an eye on this webpage if you want to stay informed about the latest news or sign up for our newsletter.
- In addition, on our new fundraising page you can read more about how you can help us in our mission. We now support the option to start your own fundraising campaign or you can donate to TRICALS directly. On our fundraising page you can read more about setting up your own campaign or you can take a look at existing ones.
- We have also listed our future events for you on our Events page. Why not find out if we have anything planned near you?
So for now, take some time to explore our new website and we hope you like it as much as we do!
Our upcoming trials
Active
Phase iii
PHOENIX trial
Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Active
Phase iii
ADORE trial
Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Recruiting
Phase iii
COURAGE-ALS Trial
Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Active
Phase ii
APL2-ALS-206 Trial
Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Active
Phase ii
RT001 in Amyotrophic Lateral Sclerosis
Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Active
Phase iii
TUDCA-ALS
Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Related news
Food and Drug Administration (FDA) approves AMX0035 (Amylyx) for the American market
During a meeting of the FDA’S Peripheral and Central Nervous System Drugs […]
Measuring treatment effects based on patient preference
To evaluate the effect of an investigational drug in ALS clinical trials, […]
TRICALS Enrols First Participants in Phase 3 MAGNET platform trial for ALS
TRICALS (the Treatment Research Initiative to Cure ALS), in collaboration with ALS […]
USA: new law promises $100 million for ALS research
A new law has been passed in the United States to give […]